Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Internal Medicine
•
Endocrinology
•
Lipid Disorders
Is moderate intensity statin plus ezetimibe just as effective as high intensity statin monotherapy in preventing major cardiovascular events?
Related Questions
Should all kidney transplant patients be started on statin therapy post operatively given their increased risk of CVD?
What is your approach to management of hyperlipidemia in patients taking JAK inhibitors?
Would you treat an isolated elevated total cholesterol in a post-menopausal patient who is otherwise healthy and has no significant CV risk factors?
When and for whom should we consider adding bempedoic acid to the lipid lowering regimen?
Is there any difference in the cardiovascular risk reduction profile of brand name vascepa versus generic icosapent ethyl for patients with hypertriglyceridemia?
Should low-intensity statins be favored to minimize the risk of diabetes onset while still offering cardiovascular benefit for patients with prediabetes where a statin is indicated?
What are the clinical indications and major limitations of lipoprotein apheresis?
How does the TACTiC trial's success with a web app for statin self-management influence your stance on nonprescription statins for primary prevention amidst statin underuse?
Do you recommend the use of bempedoic acid (Nexletol) for treatment of hyperlipidemia in patients with elevated baseline uric acid levels?
What are the indications for use of inclisiran over anti-PCSK9 monoclonal antibody therapies?
